Stockreport

Cadrenal Therapeutics Acquires VLX-1005, a First-in-Class Phase 2 12-LOX Inhibitor for Patients with Heparin-Induced Thrombocytopenia (HIT)

Cadrenal Therapeutics, Inc.  (CVKD) 
PDF Novel first-in-class therapeutic targeting a key immune signaling pathway and the underlying cause of HITIt is the first and only potent, highly selective inhibitor of h [Read more]